3D
3D0A.F Telo Genomics Corp
- Market cap
- EUR 2.36M
- P/E
- -
- P/B
- 1.98x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Mar 2026.
Is 3D0A.F undervalued?
Graham numberThe Graham number of Telo Genomics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Telo Genomics Corp fundamental analysis
No fundamental analysis for Telo Genomics Corp yet.
Telo Genomics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Telo Genomics Corp
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease ris…
Full company profileTelo Genomics Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Telo Genomics Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -9.30M | -4.61M | -1.05M | -1.31M | -1.26M | -2.11M | -2.82M | -2.72M | -2.70M | -2.19M |
| EBITDA | -9.19M | -4.48M | -971K | -1.15M | -1.01M | -2.05M | -2.79M | -2.68M | -2.69M | -2.12M |
| Net Income | -9.91M | -4.69M | -1.07M | -1.24M | -1.07M | -2.11M | -2.82M | -2.71M | -2.72M | -2.17M |
| EPS | -0.93 | -0.36 | -0.08 | -0.03 | -0.02 | -0.04 | -0.04 | -0.04 | -0.03 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 3.11M | 430K | 263K | 1.17M | 3.84M | 2.83M | 2.93M | 966K | 911K | 1.22M |
| Total Liabilities | 886K | 744K | 1.31M | 393K | 154K | 230K | 313K | 376K | 396K | 2.19M |
| Shareholders' Equity | 2.23M | -314K | -1.04M | 775K | 3.69M | 2.60M | 2.61M | 590K | 515K | -970K |
| Cash & Short-term Investments | 1.20M | 67.3K | 19.5K | 921K | 3.64M | 2.69M | 2.67M | 796K | 789K | 975K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -7.90M | -3.21M | -328K | -1.12M | -1.10M | -1.79M | -2.63M | -2.46M | -2.33M | -1.12M |
| Capital Expenditure | 254K | 23.2K | 9.31K | 9.31K | 9.31K | 25.2K | 69.1K | 5.12K | 3.25K | 300K |
| Free Cash Flow | -8.38M | -3.23M | -328K | -1.13M | -1.11M | -1.82M | -2.70M | -2.46M | -2.33M | -1.42M |
| Ratios | ||||||||||
| ROE | -445.2% | - | - | -160.2% | -29.0% | -81.1% | -108.0% | -459.8% | -527.9% | - |
| ROA | -318.5% | -1,093.0% | -409.0% | -106.2% | -27.9% | -74.5% | -96.4% | -281.0% | -298.3% | -177.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Telo Genomics Corp dividends
Telo Genomics Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Nov 22, 2019.
Who owns Telo Genomics Corp
- Insiders 2.98%
- Institutions 0.40%
- Public & others 96.62%
- Shares outstanding 100M
- Free float 97.4M
Telo Genomics Corp company profile
- Company name
- Telo Genomics Corp
- Ticker
- 3D0A.F
- ISIN
- CA87975M2085
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 555 Richmond Street West, Toronto, ON, Canada, M5V 3B1
- Phone
- 647-477-9365
- Website
- telodx.com
About Telo Genomics Corp
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with a high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM, which predicts newly diagnosed MM patients who may relapse on first-line therapy; TeloMRD-D, which identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD-detected cells in post-transplant patients. It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.
Telo Genomics Corp management
4- Mr. John Allen Farlinger C.A.CEO & Chairman of the Board · born 1959
- Dr. Sabine Mai Ph.D.Founder, Chair of the Clinical & Scientific Advisory Board and Director
- Mr. John Price CPAChief Financial Officer
- Dr. Hans Knecht M.D.Medical laboratory Director & Member of Clinical Advisory Board